U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07788586) titled 'Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial' on Aug. 18.
Brief Summary: CanTEN is a multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority phase 4 trial investigating a shortened treatment duration in patients with uncomplicated candidemia. Current guidelines recommend a 14-day treatment after documented clearance of candidemia. The traditional 14-day treatment duration for uncomplicated candidemia is not sufficiently evidence-based. In a variety of bacterial infections, shorter treatment has been proven safe and efficacious, thus reducing resistance development, toxicity...